In vivo class II transactivator expression in mice is induced by a non-interferon-gamma mechanism in response to local injury

Transplantation
T N SimsP F Halloran

Abstract

Tissue injury induces MHC class II expression, which could be important in the recognition of that tissue as an allograft. The class II transcriptional activator (CIITA) is the major regulator of basal and induced MHC class II expression and is essential for antigen presentation. The role of CIITA in the induction of class II by tissue injury is unknown. In this study, we examined CIITA induction in the course of acute ischemic or toxic renal injury in mice, including the role of interferon (IFN)-gamma and of the transcription factor, interferon regulatory factor (IRF)-1. Kidneys were injured by ischemia or by gentamicin toxicity and were then studied for changes in gene expression using Northern blot, reverse transcriptase-polymerase chain reaction, radioimmunoassay, and tissue staining. We compared wild-type (WT) mice to IFN-gamma knockout (GKO) or IRF-1 knockout mice. Ischemic injury induced CIITA and class II expression in the kidney, in WT and GKO mice. Gentamicin injury also induced both CIITA and class II expression, independent of IFN-gamma, in WT and GKO mice. After ischemic injury, the induction of class II protein levels and CIITA and class II mRNA levels were induced, to a lesser degree, in IRF-1 knockout mice. Thes...Continue Reading

References

Jan 1, 1992·Annual Review of Immunology·L H Glimcher, C J Kara
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P W FinnL H Glimcher
Oct 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·L A MatisR H Schwartz
Jan 1, 1981·Immunogenetics·P G NataliS Ferron
Nov 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S A Abdulkadir, S J Ono
Aug 10, 1995·The New England Journal of Medicine·P I TerasakiS Takemoto
Feb 1, 1995·Molecular and Cellular Biology·V BrikenP Staeheli
Feb 1, 1995·The Journal of Experimental Medicine·C H Chang, R A Flavell
Jan 12, 1995·The New England Journal of Medicine·B Mach
Jan 1, 1994·Journal of the American Society of Nephrology : JASN·R Safirstein
Jan 1, 1996·Annual Review of Immunology·B MachW Reith
Jan 1, 1996·Critical Reviews in Immunology·W M RohnE N Benveniste
Jan 1, 1997·Immunogenetics·A M LennonC Alcaïde-Loridan

❮ Previous
Next ❯

Citations

Dec 20, 2011·Cell Stress & Chaperones·Bettina BidmonChristoph Aufricht
May 20, 1999·Transplantation Proceedings·X J YuanT J Gill
May 20, 1999·Transplantation Proceedings·X J YuanT J Gill
Dec 30, 1999·Microbes and Infection·T N Sims, P F Halloran
Dec 30, 1999·Microbes and Infection·J D FontesB M Peterlin
Jul 10, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·T N SimsP F Halloran
Aug 24, 1999·Current Opinion in Nephrology and Hypertension·W W Hancock
Aug 26, 1999·Transplant International : Official Journal of the European Society for Organ Transplantation·C JohnssonG Tufveson
Aug 11, 2000·Molecular and Cellular Biology·J A Harton, J P Ting
Jul 9, 2004·Reproductive Biology and Endocrinology : RB&E·Shawn P MurphyRenae Holtz
May 16, 2009·Journal of the American Society of Nephrology : JASN·Yanxia WangChristopher Y Lu
Mar 22, 2000·Current Opinion in Urology·D Y ChanL R Kavoussi
Apr 30, 2002·International Immunology·Rodrigo NavesMaria Rosa Bono
Oct 22, 2003·Journal of the American Society of Nephrology : JASN·Oki TakeuchiPhilip F Halloran
Feb 9, 2000·Journal of the American Society of Nephrology : JASN·Yutaka TakeiPhilip F Halloran

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.